The Venture Codex

Participated · Series B · Oct 2022

FEMSelect develops EnPlace®, a minimally invasive, meshless system for pelvic floor ligament fixation cleared by the FDA to manage symptomatic uterine prolapse. The technology enables a procedure in under 30 minutes, and clinical studies report women can return to normal activities within a few days. FEMSelect has partnered with LiNA Medical USA and has spent the past year educating physicians on the technology. The company obtained a CMS procedure code earlier this year, enabling healthcare facilities to receive reimbursement for the procedure. EnPlace is currently available in more than 25 US states. FEMSelect plans to use the Series B proceeds to support growth and market penetration of EnPlace, primarily in the US; the company is led by Co-CEOs Debbie Garner and Renee Selman. POP Medical Solutions Ltd. develops NeuGuide, a minimally-invasive, meshless and dissectionless surgical system to treat pelvic organ prolapse (POP). NeuGuide combines a Nitinol-based anchor, surgical sutures and an innovative attachment method and has received FDA clearance. The device was tested in a 15-patient trial in Israel and is currently being used by US physicians in a post-marketing study. POP plans to use new funding to complete the post-marketing study, obtain European CE Mark certification, transfer the product to mass production, and build a US commercial organization for an early 2019 launch. CEO Deborah Garner leads the company and MABA founder Bernie Rudnick will join POP's board as part of the financing.

Led · Series A · Mar 2022

CVAid Medical has developed an AI-driven platform that enables neurological examinations from smartphone video and voice recordings, processing image and audio data in the cloud with in-house algorithms for real-time analysis and comparison with stored medical records. The system provides clinicians with immediate diagnostic output on whether a patient has had a stroke and an assessment of severity, plus tools to support rapid treatment decisions. The technology is also designed for use by non-professionals (e.g., retirement-home staff or family members) to enable early detection, coordinate evacuation, and ready hospital teams before ambulance arrival. The company has conducted clinical trials at hospitals in Israel and Europe and has examined hundreds of patients. Led by CEO Oren Dror and founded in 2018, CVAid plans to expand operations and accelerate its business reach using the new funds.

Participated · Equity · Feb 2015

Vectorious has developed a miniature wireless sensory implant and an external home unit that provide daily, ‘push-button’ left atrial pressure readings to give early physiological indication of cardiac decompensation. The system is designed for minimally invasive delivery and aims to improve CHF patient quality of life and reduce hospital readmissions by enabling optimized, physician-managed closed-loop therapy. The device measures left atrial pressure directly and transmits easy-to-access data for outpatient monitoring. According to the company the implant is safe and intended for low‑risk delivery with reduced long‑term complications. Commercial availability is currently limited—the device is not available for sale in the United States or internationally. Financially, Vectorious has secured venture and grant funding including a $9.5M Series B and earlier grants from the Israel Innovation Authority and a $2.2M Horizon 2020 award. Vectorious Medical Technologies is a Tel Aviv, Israel-based medical device company developing an implantable cardiac monitoring system for patients with congestive heart failure. The system leverages miniature sensing and wireless communications to enable daily readings of left atrial pressure. Led by founder and CEO Oren Goldstein, the company aims to advance continuous hemodynamic monitoring for CHF management. Vectorious closed a $5M financing to fund further development and clinical initiation. The company plans to use the proceeds to initiate first-in-human trials in collaboration with senior cardiologists from the U.S. and Israel.